Ixekizumab is under clinical development by Eli Lilly and Co and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ixekizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ixekizumab (Taltz) is under development for treatment of type 1 diabetes, axial spondyloarthritis, juvenile arthritis, ankylosing spondylitis, psoriatic arthritis, pityriasis rubra pilaris, hidradenitis suppurativa, Netherton syndrome, erythrokeratodermia variabilis and erythrokeratoderma progressive symmetrica. It is a humanized immunoglobulin, (IgG4) monoclonal antibody. It is formulated as the solution for subcutaneous administration. It was also under development for the treatment of rheumatoid arthritis, bullous pemphigoid, pyoderma gangrenosum, pityriasis rubra pilaris (PRP).
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
For a complete picture of Ixekizumab’s drug-specific PTSR and LoA scores, buy the report here.